Differanisole A, a novel antitumor antibiotic, enhances growth inhibition and differentiation of human myeloid leukemia cells induced by 9-cis retinoic acid  by Kanatani, Yasuhiro et al.
 .Biochimica et Biophysica Acta 1359 1997 71–79
Differanisole A, a novel antitumor antibiotic, enhances growth inhibition
and differentiation of human myeloid leukemia cells induced by 9-cis
retinoic acid
Yasuhiro Kanatani a,b, Makoto Makishima a, Ken-ichi Asahi c, Akira Sakurai c,
Nobutaka Takahashi c, Kazuo Motoyoshi b, Naokazu Nagata b, Yoshio Honma a,)
a Department of Chemotherapy, Saitama Cancer Center Research Institute, 818 Komuro, Ina, Saitama 362, Japan
b Third Department of Internal Medicine, National Defence Medical College, Tokorozawa, Saitama 359, Japan
c ( )The Institute of Physical and Chemical Research RIKEN , Wako, Saitama 351-01, Japan
Received 17 June 1997; accepted 18 July 1997
Abstract
Differanisole A, 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic acid, inhibited growth of human myeloid leukemia
cells. The compound induced G arrest and granulocytic differentiation of HL-60 cells, although the differentiation-inducing1
 .effect was modest. Differanisole A and 9-cis retinoic acid 9cisRA synergistically inhibited the growth and induced
functional and morphologic differentiation of HL-60 and NB4 cells, whereas the combined treatment with differanisole A
and all-trans retinoic acid or 1a ,25-dihydroxyvitamin D was less effective. Similar results were obtained in primary3
culture of leukemia cells from a patient with acute promyelocytic leukemia. The synergistic effect on growth inhibition and
induction of differentiation required simultaneous treatment with differanisole A and 9cisRA. Differanisole A and an
 .RXR-specific ligand Ro47-5944 cooperatively inhibited the cell growth, while the combined effect of differanisole A and
an RAR-specific ligand Am80 was just additive. Differanisole A in combination with 9cisRA may have implications for
therapy of acute promyelocytic leukemia patients. q 1997 Elsevier Science B.V.
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1. Introduction
Retinoids are natural morphogen in vertebrate de-
w xvelopment 1,2 and also induce differentiation of
w xmyeloid leukemia cells 3–5 . Most of patients with
Abbreviations: 9cisRA, 9-cis retinoic acid; ATRA, all-trans
retinoic acid; VD3, 1a ,25-dihydroxyvitamin D ; RAR, retinoic3
acid receptor; RXR, retinoid=receptor; IC , concentration of50
drug required for 50% inhibition of cell growth; APL, acute
promyelocytic leukemia
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 .acute promyelocytic leukemia APL are achieved
 .complete remission by all-trans retinoic acid ATRA
w x6–8 . DIF-1, a morphogen of cellular slime mold,
Dictyostelium discoideum, induced erythroid differen-
w xtiation of human and murine leukemia cells 9 . Dif-
feranisole A was isolated from the metabolites of a
simple eukaryote, Chaetomium, as the differentiation
inducer of human and murine erythroleukemia cells
w x10 . Structure of the compound is closely similar to
that of DIF-1 and differanisole A also induces the
w xdifferentiation in Dictyostelium discoideum 11 .
These results suggest that some morphogens in devel-
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 .PII S0167-4889 97 00099-2
( )Y. Kanatani et al.rBiochimica et Biophysica Acta 1359 1997 71–7972
opment beyond species affect differentiation of hu-
man leukemia cells and might be clinically useful for
treatment of acute myeloid leukemia.
Differanisole A had antitumor activity against mice
w xinoculated with neuroblastoma C-1300 cells 12 . Al-
though the compound effectively induced erythroid
differentiation of mouse erythroleukemia B8 cells, it
was less effective in inducing differentiation of
w xmyeloid leukemia cells 12 . Then, we examined the
combined effect of differanisole A and some differen-
tiation inducers on growth inhibition and induction of
differentiation of human myeloid leukemia cells.
2. Materials and methods
2.1. Chemicals
Differanisole A 3,5-dichloro-2-hydroxy-4-
.methoxy-6-n-propylbenzoic acid, Fig. 1 was pre-
w xpared as described previously 13,14 . ATRA and
 .nitroblue tetrazolium NBT were purchased from
 .Sigma Chemicals St. Louis, MO . 1a ,25-Dihy-
 .droxyvitamin D VD3 and 9cisRA were obtained3
 .from Wako Pure Chemical Industry Osaka, Japan
and BIOMOL Research Laboratories Plymouth
.Meeting, PA, USA , respectively. Retinoic acid re-
 . w xceptor RAR -specific ligand Am80 15 was a gift of
 .Prof. K. Shudo University of Tokyo, Tokyo, Japan .
 . w xRo47-5944, a retinoid= receptor RXR ligand 16 ,
was a gift of F. Hoffmann-La Roche Basel, Switzer-
.land .
2.2. Cell lines and cell culture
Human myeloid leukemia cell lines were cultured
in suspension with RPMI-1640 medium supple-
Fig. 1. Structure of differanisole A.
Table 1
DNA histogram of HL-60 cells treated with differanisole A
 .  .Differanisole A mM Cell cycle distribution %"SD
G S G qM1 2
0 44"5 45"1 8"1
60 45"2 44"1 11"2
120 78"5 20"2 6"2
Cells were treated with differanisole A for 72 h. Mean"SD of
three determinations.
mented with 10% fetal bovine serum at 378C in
w xhumidified atmosphere of 5% CO in air 17,18 .2
Peripheral blood from a 28-year-old male patient
 . with t 15;17 -positive APL M3 variant according to
the criteria devised by the French-American-British
.Committee was obtained with the informed consent
at onset, before therapy. To purify leukemic cells,
heparinized blood cells were mixed with an equal
volume of RPMI-1640 medium and centrifuged on
 .Ficoll-Hypaque Pharmacia, Uppsala, Sweden .
2.3. Assay of cell growth and properties of differenti-
ated cells
The cell number was counted in a model ZM
 .Coulter Counter Coulter Electronics, Luton, UK . To
 4assay differentiation, leukemia cells 5 = 10
.cellsrml were cultured with or without test com-
pounds for the indicated periods. Superoxide-gener-
ating oxidase was determined by the ability of cells
to reduce NBT upon exposure to 12-O-tetrade-
 .canoylphorbol-13-acetate TPA . NBT reduction was
assayed by incubating 1=106 cells in 1 ml RPMI
 .1640 medium containing NBT 1 mgrml and TPA
 .100 ngrml at 378C for 60 min. The percentage of
cells containing intracellular blue-black formazan
precipitates was determined microscopically and at
w xleast 200 cells were counted 19 . Morphological
differentiation was examined in cell smears stained
with May-Grunwald-Giemsa. The expression of¨
CD11b was analyzed by indirect immunofluorescent
w xstaining and flow cytometry as described 20 . Briefly,
 6.leukemia cells 2=10 were washed with phos-
 .phate-buffered saline PBS and incubated in 50 ml
of mouse anti-CD11b Mac-1; Nichirei Co., Tokyo,
.Japan in PBS containing 0.1% bovine serum albu-
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min at 48C for 30 min. The cells were washed with
PBS and incubated in 50 ml of FITC-conjugated
 .anti-mouse IgG Tago Inc., Burlingame, CA in PBS
containing 0.1% bovine serum albumin for 30 min,
washed with PBS, then analyzed in an Epics XL flow
 .cytometer Coulter Electronics . The cell cycle was
analyzed using propidium iodide-stained nuclei in a
w xfluorescence-activated cell sorter as described 20 .
2.4. Transacti˝ation assays for retinoid receptors
CV-1 cells were transfected with 200 ng of recep-
 .tor plasmid pCMX-hRAR-a , pCMX-hRXR-a , 500
ng of reporter plasmid and 300 ng of pCMX-b-gal by
using Lipofectin reagent Gibco BRL, Gaithersburg,
. w xMD 21 . The reporters used were TK-TREpx2-LUC
w x w x21 for RAR and TK-CRBPII-LUC 22 for RXR.
The cells were transfected for 18 h, and after remov-
ing the DNA-containing medium, they were incu-
bated with test compounds in medium containing
10% resin-charcoal-stripped fetal bovine serum for
24 h. Luciferase and b-galactosidase activities were
analyzed using a luminescence reader BLR-201;
.Aloka, Tokyo, Japan and a spectrophotometer
 .Hitachi, Tokyo , respectively. All transfection data
were normalized using an internal b-galactosidase
marker and represent the mean of triplicate experi-
ments.
3. Results
3.1. Effect of differanisole A on growth and differen-
tiation of human leukemia cell lines
Differanisole A dose-dependently inhibited growth
of several myeloid leukemia cells. When the cells
were treated for 5 days, the IC was 89–130 mM for50
Fig. 2. Combined effect of ATRA, 9cisRA or VD3 with differanisole A on growth inhibition and NBT reduction of HL-60 cells. Cells
 .  .  .  .  .  .were cultured with differanisole A in the presence of 0 ‘ , 3 I and 30 ’ nM VD3 or in the presence of 1 ^ , 4 I , 8 v and
 .10 B nM ATRA or 9cisRA for 5 days. The mean"SD from four separate experiments.
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ML-1, HL-60, NB4, THP-1, U937 and KU812 cells.
Differanisole A was cytostatic rather than cytotoxic
to the cells. Then we measured changes in cell cycle
distribution of HL-60 cells treated with various con-
 .centrations of differanisole A for 24–72 h Table 1 .
There was no remarkable changes in DNA histogram
of the cells treated with 60 mM differanisole A, but
the number of cells in the G phase was accumulated1
in the culture treated with 120 mM. When HL-60
cells were treated with differanisole A for 7 days, the
cells underwent slightly but significantly morphologi-
 .cal differentiation Table 2 . The functional differen-
 .tiation NBT reduction was also induced by dif-
feranisole A, although the inducing activity was mod-
 .  .Fig. 3. Expression of CD11b antigen in HL-60 cells cultured in the presence of 3 nM VD3 upper panel , 4 nM ATRA middle panel , or
 .  .  .4 nM 9cisRA bottom panel in the presence or absence - - - of 60 mM differanisole A for 3 days. The expression was
evaluated by immunofluorescent staining using anti-CD11b monoclonal antibody. In each panel, the thin line represents untreated control
and the dotted line represents the negative control for immunofluorescence.
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 .est data not shown . The weak differentiation-induc-
ing activity of differanisole A was also observed in
monocytic leukemia U937 cells and erythroleukemia
 .K562 cells data not shown .
3.2. Combined effect of differanisole A and differenti-
ation inducers
Next we examined effect of differanisole A on
growth and differentiation of leukemia cells in the
presence of ATRA, 9cisRA or VD3. Differanisole A
enhanced growth inhibition and induction of NBT
reduction of HL-60 cells induced by 9cisRA, ATRA
 .or VD3 Fig. 2 . Differanisole A exhibited more than
additive effect with 9cisRA in growth inhibition and
induction of NBT reduction. Similar results were
obtained in expression of CD11b surface antigen,
which is another myelomonocytoid differentiation
 .marker Fig. 3 . The co-operative effect of dif-
feranisole A and 9cisRA was also observed in pro-
 .myelocytic leukemia NB4 cells with t 15;17 chro-
 .mosomal translocation Fig. 4 .
3.3. Requirement of simultaneous treatment for syn-
ergistic effect of differanisole A and 9cisRA
Effect of the time addition of differanisole A and
9cisRA on the growth inhibition and NBT reduction
 .of NB4 cells was examined Table 3 . Preincubation
of NB4 cells with differanisole A for 24 h did not
essentially affect the 9cisRA-induced growth inhibi-
 .tion and NBT reduction regimen 3 vs. 6 . 9cisRA
also did not prime the growth inhibition induced by
 .differanisole A regimen 2 vs. 8 . Similar results
were obtained when the cells were pretreated with
 .differanisole A or 9cisRA for 72 h data not shown .
On the other hand, simultaneous treatment with 4 nM
 .9cisRA and 60 mM differanisole A regimen 4
Fig. 4. Combined effect of ATRA, 9cisRA or VD3 with differanisole A on growth inhibition and NBT reduction of NB4 cells. Cells were
 .  .  .  .  .cultured with differanisole A in the presence of 0 ‘ , 3 ^ , and 30 ’ nM VD3 or in the presence of 4 I and 40 B nM ATRA or
9cisRA for 5 days. The mean"SD from four separate experiments.
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Table 2
Induction of morphological differentiation of HL-60 cells by differanisole A
 .  .  .Differanisole A mM Cell growth % of control Morphological changes %
BlaqPro Mye Met Neu
0 100"7 87"5 10"3 3"1 0
60 85"5 65"4 17"3 5"3 13"1
120 40"5 45"4 25"2 8"3 22"5
180 15"3 34"4 23"2 10"3 33"2
 4 .HL-60 cells 5=10 rml were treated with differanisole A for 7 days. Mean"SD of three separate experiments.
Table 3
Growth inhibition and NBT reduction in NB4 cells treated with differanisole A and 9cisRA
 .  .Regimen Treatment Cell growth % of control NBT reduction % of positive cells
0–1 1–6 days
1 none none 100"2 5.2"0.7
2 none Dif 83"4 14.2"0.9
3 none 9cRA 113"9 47.4"3.7
4 none Difq9cRA 42"5 89.2"7.2
5 Dif none 105"7 4.4"0.6
6 Dif 9cRA 115"3 44.5"3.6
7 9cRA none 109"3 4.9"0.5
8 9cRA Dif 95"1 7.8"0.6
 .  .NB4 cells were treated with 60 mM differanisole A Dif or 4 nM 9cisRA 9cRA for 1 day, and then cultured with fresh culture medium
with 60 mM differanisole A or 4 nM 9cisRA for further 5 days. Means"SD of three experiments.
Fig. 5. Growth inhibition of HL-60 cells treated with differanisole A, Am80, ATRA and Ro47-5944. Cells were treated with various
 .  .  .  .  .  .concentrations of Am80 A or Ro47-5944 B in the presence of 0 ‘ , 30 ^ , 60 I , or 90 B mM differanisole A for 5 days. C;
 .  .  .cells were treated with various concentrations of Ro47-5944 in the presence of 0 ‘ , 40 ’ or 400 l nM ATRA for 5 days. The
mean"SD from four separate experiments.
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greatly induced the growth inhibition and NBT reduc-
tion, suggesting that the simultaneous treatment is
required for the synergism.
3.4. Combined effect of differanisole A with RXR or
RAR ligands
Retinoid signals are mediated by RAR and RXR,
then the ligand-activated receptors dimerize and bind
w xRAR response element 23–28 . The binding affinity
of RARrRXR to the DNA sequence reportedly re-
flects RAR-mediated transcriptional activity. 9cisRA
is a ligand for both RAR and RXR, while ATRA is a
w xligand for RAR alone 29,30 . However, ATRA can
be metabolized to 9cisRA to some extent. To under-
stand the nature of differanisole A, we examined the
cooperative effect of differanisole A with RAR-
specific or RXR-specific ligand. HL-60 cells were
treated with various concentrations of Am80 or
Ro47-5944 in the presence of differanisole A. Fig. 5
shows that the growth-inhibitory effect of Am80 and
differanisole A was just additive, while the effect of
Ro47-5944 and differanisole A was synergistic.
ATRA also synergistically inhibited the growth of
 .HL-60 cells in the presence of Ro47-5944 Fig. 5 .
Peripheral blood mononuclear cells )80% blasts
.and promyelocytes were isolated from an APL pa-
 .tient 20 000rml of white blood cell count . The
Fig. 6. Induction of NBT reduction of APL cells by differanisole
A and retinoids in primary culture. Cells were cultured with
 .various concentrations of retinoids in the presence of 0 ‘ , 30
 .  .^ , or 60 I mM differanisole A for 7 days. The mean"SD
of triplicates.
Table 4
Effect of differanisole A on transactivation of retinoid receptor
Receptor Reporter Luciferase induction
 .ratio
DIF ATRA 9cisRA
pCMX TK-TREx2-LUC 1.0 4.6 NT
pCMX-RARa 1.2 40.8 NT
pCMX-RXRa TK-CRBPII-LUC 0.9 NT 4.6
CV-1 cells transfected with the plasmids were incubated without
y4  . -6 y7or with 10 M differanisole A DIF , 10 M ATRA, or 10 M
9cisRA for 24 hours. pCMX is an empty vector and the genes of
RAR a and RXR a were introduced into the vector. Values are
the ratio compared with luciferase activity in the unstimulated
cells, and represent the mean of triplicates. NT, not tested.
leukemia cells responded to ATRA and 9cisRA, but
 .not to differanisole A alone Fig. 6 . Differeanisole A
significantly enhanced the retinoid-induced NBT re-
duction of the cells 88% NBT-positive in 0.4 nM
9cisRA plus 60 mM differanisole A, whereas 40% in
.0.4 nM 9cisRA alone . The enhancing effect of dif-
feranisole A was also observed in morphological
changes of the cells treated with 9cisRA data not
.shown .
3.5. Effect of differanisole A on transacti˝ation of
retinoid receptors
There is a possibility that differanisole A may act
at least partly as an RAR agonist. Therefore, we
transfected CV-1 cells with receptor plasmid
 .pCMX-hRAR a and pCMX-hRXR-a and lu-
ciferase reporter plasmids, and examined effect of
differanisole on the receptor-mediated transactivation.
Differanisole A did not stimulate transactivating ac-
tivity of RAR a on the TK-TREpx2-LUC reporter,
 .although ATRA greatly enhanced Table 4 . Dif-
feranisole A was also not effective on RXR. These
results indicate that differanisole A is not an agonist
for RAR or RXR.
4. Discussion
Differanisole A inhibits the growth and enhances
the differentiation of myeloid leukemia cells. The
cooperative effect of differanisole A with 9cisRA
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was more prominent than that with ATRA or VD3 in
growth inhibition and differentiation induction.
9cisRA is a stereoisomer of ATRA and activates both
w xRARs and RXRs 29,30 . The natural RXRrRAR
ligand and ATRA synergistically inhibited growth
and induced differentiation of ATRA-resistant HL-60
w xcells 31 . Moreover, synthetic agonists for RARs and
RXRs can synergistically promote differentiation of
w xHL-60 and NB4 cells 16,32 . Differanisole A and
9cisRA also synergistically inhibited the growth of
HL-60 cells, but the combined effect of differanisole
A and the RAR-specific ligand Am80 was just addi-
tive. The growth-inhibitory effect of differanisole A
and RXR-specific ligand Ro47-5944 was more than
additive. Simultaneous treatment with differanisole A
and 9cisRA was required for their synergistic action.
However, differanisole A does not act as an RAR or
 .RXR agonist Table 4 . Differanisole A can induce
erythroid differentiation of K562 cells, but ATRA is
failed to induce the differentiation, which suggest that
 .differanisole A has the other action s in inducing
differentiation of leukemia cells. Retinoid receptors
exert their regulatory functions by acting as both
w xactivators and repressers of gene expression 33 .
Balance of orphan receptors and their heterodimeriza-
w xtion can modulate retinoid sensitivity 34 . Dif-
feranisole A might affect the activators andror re-
pressers. Alternatively, differanisole A might be a
ligand of an orphan receptor and act on formation of
the heterodimer with RXR.
9cisRA was more potent than ATRA in inhibiting
growth and inducing differentiation of myeloid
w xleukemia cells in vitro 35 , but differentiation ther-
apy with 9cisRA was not superior to that with ATRA
on APL patients. The synergistic potential of dif-
feranisole A and 9cisRA allows reduced concentra-
tions of the individual compounds to achieve induc-
tion of differentiation, and this may extend the thera-
peutic use by avoiding the side effects of 9cisRA.
Although most APL was achieved complete remis-
sion by ATRA therapy, some of them relapsed and
developed ATRA-resistant. A potential mechanism
for clinical ATRA resistance is the pharmacologic
w xalteration in the metabolism of ATRA 36 . Continu-
ous treatment with ATRA in APL is associated with
progressive reduction of plasma concentrations of
ATRA, possibly due to induction of cytochrome P-
450 enzymes and the increased expression of cellular
w xretinoic acid-binding protein 37,38 . On the other
hand, 9cisRA does not induce its own catabolism.
Combination with 9cisRA and other differentiation
inducers such as differanisole A might be more use-
ful in treatment of APL patients. Since differanisole
A has antitumor activity in a mouse experimental
model, it would be interesting to study anti-leukemic
effect of combination with differanisole A and 9cisRA
on experimental models inoculated with ATRA-re-
sistant leukemia cells.
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